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64 Is mixing of tobramycin and colistimethate-sodium containing
inhalation solutions a good idea?
A. Bucholski1, R. Egle1, G. Lang1, O. Denk1, M. Knoch1. 1PARI Pharma GmbH,
Gra¨felﬁng, Germany
Objective: Patients suffering from bacterial infections of the lungs are frequently
treated by alternating or combining the inhaled antibiotics tobramycin (aminoglyco-
side) and colistimethate-sodium (CMS, i.e. polymyxin E). Therefore, patients might
feel encouraged to mix solutions of both antibiotics in order to inhale the mixture
in one single inhalation session. As the effects of preparing such a mixture on
physical and chemical stability of the solution are not known, an evaluation was
triggered.
Methods: Vials of tobramycin solution (170mg/1.7ml) were mixed with recon-
stituted CMS (2 Mio. IU CMS dissolved in 4ml of 0.9% saline) and physico-
chemically characterized with respect to osmolality, viscosity, surface tension and
pH. Additionally, the tobramycin content and possible tobramycin related impurities
were assayed by HPLC.
Results and Conclusion: Mixtures of the antibiotics did not show obvious signs of
physicochemical incompatibilities. However, the measured content of tobramycin
in the mixture decreased to 70−75% of the initial amount within about 12 hours.
Already 10 minutes after mixing a marked decrease of tobramycin content (approx.
−7%) was observed indicating a fairly rapid reaction or decomposition immediately
after preparation and during treatment. Therefore, mixing of tobramycin containing
solutions with CMS prior to inhalation cannot be recommended.
65 The effectiveness of nebulised tobramycin over a 3 year period
D. Nazareth1, R. Sapina-Vivo1, J. Gallagher1, S.M.H. Kazmi1, J. Greenwood1,
M.J. Ledson1, M.J. Walshaw1. 1Liverpool Adult CF Unit, Liverpool, United
Kingdom
Background: Although guidelines recommend that all CF patients chronically in-
fected with Pseudomonas aeruginosa are offered prophylactic nebulised antibiotics
(including high dose tobramycin, HDNT) to limit exacerbations and slow the rate
of decline in lung function, their use has only been evaluated in a clinically stable
population. However, HDNT is expensive and in the UK is often used as second
line therapy, when patients are unstable or deteriorating on other treatments. We
wished to determine whether HDNT is still effective in this patient group.
Method: We looked at the effect of HDNT in 54 patients in our adult clinic who
were prescribed this as a second line treatment, comparing pre-treatment clinical
parameters with those for the subsequent 3 years. Forty were also taking nebulised
colomycin in the month off HDNT.
Results: The results are expressed as median (inter-quartile range) in the table.
There was an improvement in FEV1, and FVC and a reduction in iv days at 2 years
following commencement of HDNT.
Conclusion: This study demonstrates that HDNT is still effective when used as a
second line agent in unstable deteriorating patients.
Table: Effect of nebulised tobramycin [median (IQ range)]
FEV1% FVC % iv days (Inpatient)
Pre-commencement 49 (43−62) 77 (65−88) 22 (14−41)
1 year post 49 (40−68) 76 (64−89) 28 (11−61)
2 years post 54 (42−72) 83 (65−92) 20 (0−41)
3 years post 49 (42−68) 80 (63−87) 25 (14−46)
66 Efﬁcacy of tobramycin inhalation powder (TIP) versus other
inhaled antibiotics in cystic ﬁbrosis (CF) patients with chronic
P. aeruginosa infection: a network meta-analysis
M.-M. Balp1, G. Capkun-Niggli1, K. Littlewood2, G. Do¨ring3, G. Angyalosi1.
1Novartis Pharma AG, Basel, Switzerland; 2Mapi Consultancy, Houten,
Netherlands; 3University of Tu¨bingen, Tubingen, Germany
Objective: Inhaled antibiotics prescribed to treat CF patients with chronic P. aerug-
inosa infection have been shown to improve lung function. The relative efﬁcacy of
inhaled antibiotics is not known, as few comparative studies are available. The
efﬁcacy of tobramycin inhalation powder capsules (TIP), tobramycin inhalation
solutions (TIS-T and TIS-B), colistimethate sodium (Colistin) and aztreonam lysine
for inhalation (AZLI) was compared.
Methods: A systematic search found seven relevant randomised controlled trials
in CF patients with moderate to severe lung function impairment. Percent change
from baseline in FEV1% predicted at 4 weeks of treatment was analysed using
network meta-analysis techniques, combining direct and indirect treatment evidence.
Several covariates including prior exposure to active drug, considered as a potential
treatment effect modiﬁer, were included in the analysis.
Results: Two studies had patients with mean age <18 and ﬁve with mean age
>18 years. Two studies had patients previously exposed to active drug, and ﬁve had
naive to study drug patients. Mean baseline FEV1% predicted was between 50% and
64%. TIP, TIS-T and TIS-B had comparable efﬁcacy in improving FEV1% predicted
at 4 weeks. TIP was comparable to all treatments, although point estimates may
suggest a trend for better efﬁcacy than Colistin and AZLI for this endpoint: TIP
versus Colistin: −5.8 (CrI: −12.8; 1.2) and TIP versus AZLI: −3.6 (CrI: −8.3; 1.0).
Conclusion: The analysis suggests that TIP is at least as efﬁcacious as other inhaled
antibiotics for lung function improvement at 4 weeks of treatment.
67 Trends in health-related quality of life (HRQoL) in cystic ﬁbrosis
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A.L. Quittner1, M. Higgins2, G. Angyalosi3, F. Brockhaus3, K. Thomas2,
J. Zhang4. 1University of Miami, Miami, United States; 2Novartis Horsham
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Switzerland; 4Novartis Pharmaceuticals Corporation, East Hanover, United States
Objective: Tobramycin inhalation powder (TIP) is a novel drug-device combination
designed to deliver tobramycin topically to the lungs. The EDIT trial evaluated
efﬁcacy, safety and HRQoL in patients treated with TIP.
Methods: Patients with cystic ﬁbrosis and Pseudomonas aeruginosa (Pa) infection,
inhaled anti-pseudomonal-naive (for past 4 months), aged 6−21 years and FEV1%
predicted 25−80% were randomized to TIP 112mg b.i.d. or placebo (double-blind)
for a single treatment cycle. In addition to primary and secondary assessments of
spirometric and Pa suppressive efﬁcacy, HRQoL was assessed as an exploratory
endpoint by the 12-item Revised Cystic Fibrosis Quality of Life Questionnaire
(CFQ-R; Quittner et al. 2005).
Results: 62 patients were randomized (32/30 TIP/placebo). At Day 29 TIP pa-
tients demonstrated clinically relevant improvements (>8 points from baseline)
on Respiratory Symptoms Scale (8.3 points), Role Functioning (8.3 points) and
Health Perceptions (11.1 points) domains vs virtually no change for those on
placebo. Treatment differences (TIP-placebo) at Day 29 were 11.1 points (p = 0.076)
for Respiratory Symptoms; 8.3 points (p = 0.20) for Role Functioning and 22.2
points (p = 0.006) for Health Perception. Both groups improved by 11.1 points
in the Treatment Burden domain, indicating that the delivery device may be less
burdensome than a conventional nebulizer.
Conclusion: Pulmonary function measures alone may not correspond to patient
perception of illness severity. TIP provided some meaningful improvements in
HRQoL, notably in the Respiratory Symptoms domain, reﬂecting positive trends in
FEV1 and Pa suppression.
